#United States #Chicago #ASCO 2025 #Foresight Diagnostics #MRD Detection

Foresight Diagnostics Unveils New Insights at ASCO 2025

In a remarkable development for cancer diagnostics, Foresight Diagnostics, Inc. will present cutting-edge data on ultra-sensitive minimal residual disease (MRD) detection during the highly anticipated 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. This event is set to take place from May 30 to June 3, 2025, in Chicago, Illinois, and signals a pivotal moment in cancer treatment precision.

The Presentation Details

Foresight’s presentation will focus on newly diagnosed diffuse large B-cell lymphoma (DLBCL), a common and aggressive form of non-Hodgkin lymphoma. The company will conduct an oral presentation in collaboration with Amsterdam University Medical Centers (Amsterdam UMC), where significant validation results of its Foresight CLARITY™ MRD detection technology will be highlighted. Additionally, a trial-in-progress poster will be showcased regarding the SHORTEN-ctDNA clinical trial in partnership with Columbia University, emphasizing the ongoing advancements in MRD testing.

The innovative Foresight CLARITY™ technology utilizes the proprietary PhasED-Seq™ method, promising exceptional analytical sensitivity, capable of detecting MRD to levels of less than 1 part per million in B-cell lymphoma patients. This precision is crucial in oncology, as it allows for earlier intervention and tailored treatment plans, potentially increasing the survival rates of patients.

Key Statements from Foresight

Dr. David Kurtz, the Chief Medical Officer at Foresight Diagnostics, emphasized the significance of these presentations: “These presentations mark important clinical validation milestones for our Foresight CLARITY platform. Our ultra-sensitive MRD detection at the end of first-line therapy identifies DLBCL patients at significantly higher risk of relapse.”

He further elaborated on the SHORTEN-ctDNA study, stating, “This study investigates how MRD testing can guide de-escalation strategies in newly diagnosed patients, aiming to equip oncologists with vital data that enhances treatment decisions and, ultimately, patient outcomes.”

Presentation Formats at ASCO 2025

Oral Presentation

• - Title: Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national trial.
• - Presenter: Steven Wang, MD, PhD (Amsterdam UMC)
• - Session: Oral Abstract Session – Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
• - Date and Time: Friday, May 30 | 2:45 PM – 5:45 PM CDT
• - Location: Room S100a or accessible via live stream for virtual attendees
• - Abstract Number: 7000

Poster Presentation

• - Title: Sequencing-guided Chemotherapy Optimization Using Real-Time Evaluation in Newly Diagnosed DLBCL With Circulating Tumor DNA SHORTEN-ctDNA (NCT06693830)
• - Presenter: Stephanie Meek, PhD (Foresight Diagnostics)
• - Session: Poster Session – Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
• - Date and Time: Sunday, June 1 | 9:00 AM – 12:00 PM CDT
• - Abstract Number: TPS7096
• - Poster Board Number: 272a

Visiting Foresight at ASCO

Foresight Diagnostics will also have a presence at the event, located in the Innovation Hub #3. Attendees interested in learning more about their activities and advancements in MRD detection are encouraged to visit their booth and explore how this technology is reshaping approaches to cancer treatment.

For more information about Foresight Diagnostics and its pioneering work, please visit their website at foresight-dx.com and follow them on social media platforms like X, LinkedIn, and Bluesky. Note: Foresight CLARITY™ IUO is categorized as an investigational device, limited by United States law to investigational use only.